The contents provided by this page is intended for patients prescribed with Remsima®. If you are an Australian Healthcare Professional , please click the button to the right.
How Remsima® works
Remsima® Mode of Action1,2
Remsima® contains the active substance called infliximab.
Infliximab acts by binding to a special protein in the body called tumour necrosis factor alpha (TNF-α).
In people with diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis,
psoriatic arthritis and psoriasis, the body produces too much TNF-α, which can cause the body's immune system to attack
normal healthy parts of the body. Remsima® can block the damage caused by too much TNF-α.
Reference
1. Remsima® Australian Consumer Medicine Information (CMI) PF pen. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-CMI-01619-1 Accessed January 2023.
2. Remsima® Australian Consumer Medicine Information (CMI) PF syringe. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-CMI-01618-1 Accessed January 2023.
Abbreviation
TNF-α: tumor necrosis factor alpha